Compare FRT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | CYTK |
|---|---|---|
| Founded | 1962 | 1997 |
| Country | United States | United States |
| Employees | 320 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 7.6B |
| IPO Year | N/A | 2004 |
| Metric | FRT | CYTK |
|---|---|---|
| Price | $106.79 | $63.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 18 |
| Target Price | ★ $110.71 | $87.56 |
| AVG Volume (30 Days) | 795.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $5.71 | $9.79 |
| Revenue Next Year | $4.65 | $302.66 |
| P/E Ratio | $22.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $80.65 | $29.31 |
| 52 Week High | $110.89 | $70.98 |
| Indicator | FRT | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 50.87 |
| Support Level | $98.70 | $59.25 |
| Resistance Level | $108.54 | $65.93 |
| Average True Range (ATR) | 1.93 | 2.54 |
| MACD | -0.37 | -0.34 |
| Stochastic Oscillator | 40.01 | 42.07 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 27.4 million square feet of retail space and 3,000 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.